Evidence map›Paper›PMID 25993602›Full record

ArticleJournal of visualized experiments : JoVE2015

Pairwise growth competition assay for determining the replication fitness of human immunodeficiency viruses.

Siriphan Manocheewa, Erinn C Lanxon-Cookson, Yi Liu, J Victor Swain, Jan McClure, Ushnal Rao, Brandon Maust, Wenjie Deng, Justine E Sunshine, Moon Kim and 2 more

Abstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. HIV-1 Vpr counteracts HLTF-mediated restriction of HIV-1 infection in T cells.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Siriphan ManocheewaDepartment of Microbiology, University of Washington.
Erinn C Lanxon-CooksonDepartment of Microbiology, University of Washington.
Yi LiuDepartment of Microbiology, University of Washington.
J Victor SwainDepartment of Microbiology, University of Washington.
Jan McClureDepartment of Microbiology, University of Washington.
Ushnal RaoDepartment of Microbiology, University of Washington.
Brandon MaustDepartment of Microbiology, University of Washington.
Wenjie DengDepartment of Microbiology, University of Washington.
Justine E SunshineDepartment of Microbiology, University of Washington.
Moon KimDepartment of Microbiology, University of Washington.
Morgane RollandU.S Military HIV Research Program, Walter Reed Army Institute of Research; Henry M. Jackson Foundation.
James I MullinsDepartment of Microbiology, University of Washington; Departments of Medicine and Laboratory Medicine, University of Washington; jmullins@u.washington.edu.
University of Washington · USHenry M. Jackson Foundation · US

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Kenneth Sherr · 1988 to 2026
$104.9M
Viral Determinants of HIV-1 Transmission in African HeterosexualsP01AI057005 · NIAID · UNIVERSITY OF WASHINGTON · PI COREY, LAWRENCE · 2003 to 2014
$20.5M
Occurrence and Outcome of Dual HIV-1 InfectionR37AI047734 · NIAID · UNIVERSITY OF WASHINGTON · PI MULLINS, JAMES IVAN · 2005 to 2014
$5.9M
Mechanisms of Formation and Persistence of Active HIV ReservoirsR01AI111806 · NIAID · UNIVERSITY OF WASHINGTON · PI MULLINS, JAMES IVAN · 2014 to 2018
$4.3M
Role of proviral loci in HIV latencyR01AI125026 · NIAID · UNIVERSITY OF WASHINGTON · PI MULLINS, JAMES IVAN · 2016 to 2019
$3.4M
OCCURRENCE AND OUTCOME OF DUAL HIV-1 INFECTIONR01AI047734 · NIAID · UNIVERSITY OF WASHINGTON · PI MULLINS, JAMES IVAN · 2000 to 2004
$2.4M
NIAID NIH HHS P01 AI057005NIAID NIH HHS P01AI057005NIAID NIH HHS P30 AI027757NIAID NIH HHS R01 AI047734NIAID NIH HHS R01AI047734NIAID NIH HHS R01 AI111806NIAID NIH HHS R01AI111806NIAID NIH HHS R01 AI125026NIAID NIH HHS R37 AI047734
6 · The paper itself

Abstract

In vitro fitness assays are essential tools for determining viral replication fitness for viruses such as HIV-1. Various measurements have been used to extrapolate viral replication fitness, ranging from the number of viral particles per infectious unit, growth rate in cell culture, and relative fitness derived from multiple-cycle growth competition assays. Growth competition assays provide a particularly sensitive measurement of fitness since the viruses are competing for cellular targets under identical growth conditions. There are several experimental factors to consider when conducting growth competition assays, including the multiplicity of infection (MOI), sampling times, and viral detection and fitness calculation methods. Each factor can affect the end result and hence must be considered carefully during the experimental design. The protocol presented here includes steps from constructing a new recombinant HIV-1 clone to performing growth competition assays and analyzing the experimental results. This protocol utilizes experimental parameter values previously shown to yield consistent and robust results. Alternatives are discussed, as some parameters need to be adjusted according to the cell type and viruses being studied. The protocol contains two alternative viral detection methods to provide flexibility as the availability of instruments, reagents and expertise varies between laboratories.

Indexed as

DNA ReplicationDNA, ViralHEK293 CellsHIV-1HIV Core Protein p24HumansMutationVirus ReplicationDNA, ViralHIV Core Protein p24

Identifiers

PMID25993602
PMCPMC4542137
OpenAlexW1518169535

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.